Compare real-world time-to-treatment switch and discontinuation in adult patients receiving cladribine tablets (CladT; 3.5mg/kg cumulative dose over 2 years) versus other oral disease-modifying therapies (DMTs).
No takes yet. Share an insight, caveat, or question.
Spelman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: